Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

80.0%

4 terminated/withdrawn out of 5 trials

Success Rate

20.0%

-66.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 1
2(40.0%)
Early Phase 1
1(20.0%)
5Total
Phase 2(2)
Phase 1(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01488318Phase 2Terminated

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Role: lead

NCT01051791Phase 2Terminated

Phase II Study of RAD001 Head and Neck Cancer

Role: lead

NCT02298595Phase 1Withdrawn

Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Role: lead

NCT02023931Early Phase 1Completed

Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa

Role: lead

NCT02277184Phase 1Terminated

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

All 5 trials loaded